Two Reasons to Skip Ocugen Stock Despite Some Good News

41
5
Favorite

Two Reasons to Skip Ocugen Stock Despite Some Good News

InvestorPlace2022-02-16

Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

breAkdaWn
·2022-02-19
evryone seems to be wise on hind sight
Reply
2
Report
KeeBoonTong
·2022-02-16
Lalalala
Reply
2
Report
gongfucat
·2022-02-16
Penny stock. Be v careful
Reply
2
Report
benjaminlsk
·2022-02-16
Nice
Reply
3
Report
ZhiLing
·2022-02-16
ok
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1128199198?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-16 10:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128199198","market":"us","top_or_hot":-1,"title":"Two Reasons to Skip Ocugen Stock Despite Some Good News","media":"InvestorPlace","content":"<div>\n<p>Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...</p>\n\n<a href=\"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Reasons to Skip Ocugen Stock Despite Some Good News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Reasons to Skip Ocugen Stock Despite Some Good News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...</p>\n\n<a href=\"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/","article_id":"1128199198","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128199198","pubTimestamp":1644979615,"columns":[],"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a ","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"尽管有一些好消息，但跳过Ocugen股票的两个原因","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.It’s all thanks to its coronavirus vaccine, Covaxin.Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.That’s all great news.No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.However, I wouldn’t rush to buy the stock. There are some major issues.Issue No. 1: Ocugen’s Commercialization Agreement with Bharat BiotechAt the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.Issue No. 2: OCGN Stock is Losing MoneyWorse, the company isn’t bringing in any money, and losses continue to pile up.In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to Motley Fool contributor David Jagielski:“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”Fortunately, the Vaccine Isn’t Ocugen’s Only CatalystThat being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”The Bottom Line on OCGN StockThe story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9094417622,"gmtCreate":1645213303474,"gmtModify":1676534009071,"author":{"id":"3569809505691000","authorId":"3569809505691000","name":"breAkdaWn","avatar":"https://community-static.tradeup.com/news/4c3676c14de9bfcd6f45bcf7ba4ddb6c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3569809505691000","authorIdStr":"3569809505691000"},"htmlText":"evryone seems to be wise on hind sight","listText":"evryone seems to be wise on hind sight","text":"evryone seems to be wise on hind sight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094417622","repostId":1128199198,"repostType":2,"repost":{"id":"1128199198","kind":"news","pubTimestamp":1644979615,"share":"https://ttm.financial/m/news/1128199198?lang=&edition=fundamental","pubTime":"2022-02-16 10:46","market":"us","language":"en","title":"Two Reasons to Skip Ocugen Stock Despite Some Good News","url":"https://stock-news.laohu8.com/highlight/detail?id=1128199198","media":"InvestorPlace","summary":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a ","content":"<html><head></head><body><p><b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) has been one of the most explosive stocks on the market in the last year.</p><p>From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.</p><p>It’s all thanks to its coronavirus vaccine, Covaxin.</p><p>Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.</p><p>Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.</p><p>That’s all great news.</p><p>No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.</p><p>However, I wouldn’t rush to buy the stock. There are some major issues.</p><p><b>Issue No. 1: Ocugen’s Commercialization Agreement with Bharat Biotech</b></p><p>At the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.</p><p>That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.</p><p><b>Issue No. 2: OCGN Stock is Losing Money</b></p><p>Worse, the company isn’t bringing in any money, and losses continue to pile up.</p><p>In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to <i>Motley Fool</i> contributor David Jagielski:</p><blockquote>“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”</blockquote><p><b>Fortunately, the Vaccine Isn’t Ocugen’s Only Catalyst</b></p><p>That being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.</p><p>In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.</p><p>Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”</p><p><b>The Bottom Line on OCGN Stock</b></p><p>The story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.</p><p>Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.</p><p>Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.</p><p>I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Reasons to Skip Ocugen Stock Despite Some Good News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Reasons to Skip Ocugen Stock Despite Some Good News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...</p>\n\n<a href=\"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128199198","content_text":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.It’s all thanks to its coronavirus vaccine, Covaxin.Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.That’s all great news.No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.However, I wouldn’t rush to buy the stock. There are some major issues.Issue No. 1: Ocugen’s Commercialization Agreement with Bharat BiotechAt the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.Issue No. 2: OCGN Stock is Losing MoneyWorse, the company isn’t bringing in any money, and losses continue to pile up.In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to Motley Fool contributor David Jagielski:“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”Fortunately, the Vaccine Isn’t Ocugen’s Only CatalystThat being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”The Bottom Line on OCGN StockThe story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095793730,"gmtCreate":1644983612227,"gmtModify":1676533983601,"author":{"id":"3578717603960999","authorId":"3578717603960999","name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":4,"crmLevelSwitch":1,"idStr":"3578717603960999","authorIdStr":"3578717603960999"},"htmlText":"Lalalala","listText":"Lalalala","text":"Lalalala","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095793730","repostId":1128199198,"repostType":4,"repost":{"id":"1128199198","kind":"news","pubTimestamp":1644979615,"share":"https://ttm.financial/m/news/1128199198?lang=&edition=fundamental","pubTime":"2022-02-16 10:46","market":"us","language":"en","title":"Two Reasons to Skip Ocugen Stock Despite Some Good News","url":"https://stock-news.laohu8.com/highlight/detail?id=1128199198","media":"InvestorPlace","summary":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a ","content":"<html><head></head><body><p><b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) has been one of the most explosive stocks on the market in the last year.</p><p>From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.</p><p>It’s all thanks to its coronavirus vaccine, Covaxin.</p><p>Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.</p><p>Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.</p><p>That’s all great news.</p><p>No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.</p><p>However, I wouldn’t rush to buy the stock. There are some major issues.</p><p><b>Issue No. 1: Ocugen’s Commercialization Agreement with Bharat Biotech</b></p><p>At the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.</p><p>That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.</p><p><b>Issue No. 2: OCGN Stock is Losing Money</b></p><p>Worse, the company isn’t bringing in any money, and losses continue to pile up.</p><p>In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to <i>Motley Fool</i> contributor David Jagielski:</p><blockquote>“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”</blockquote><p><b>Fortunately, the Vaccine Isn’t Ocugen’s Only Catalyst</b></p><p>That being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.</p><p>In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.</p><p>Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”</p><p><b>The Bottom Line on OCGN Stock</b></p><p>The story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.</p><p>Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.</p><p>Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.</p><p>I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Reasons to Skip Ocugen Stock Despite Some Good News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Reasons to Skip Ocugen Stock Despite Some Good News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...</p>\n\n<a href=\"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128199198","content_text":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.It’s all thanks to its coronavirus vaccine, Covaxin.Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.That’s all great news.No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.However, I wouldn’t rush to buy the stock. There are some major issues.Issue No. 1: Ocugen’s Commercialization Agreement with Bharat BiotechAt the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.Issue No. 2: OCGN Stock is Losing MoneyWorse, the company isn’t bringing in any money, and losses continue to pile up.In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to Motley Fool contributor David Jagielski:“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”Fortunately, the Vaccine Isn’t Ocugen’s Only CatalystThat being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”The Bottom Line on OCGN StockThe story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095475464,"gmtCreate":1644980678043,"gmtModify":1676533983164,"author":{"id":"4101213092270660","authorId":"4101213092270660","name":"gongfucat","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":0,"idStr":"4101213092270660","authorIdStr":"4101213092270660"},"htmlText":"Penny stock. Be v careful","listText":"Penny stock. Be v careful","text":"Penny stock. Be v careful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095475464","repostId":1128199198,"repostType":4,"repost":{"id":"1128199198","kind":"news","pubTimestamp":1644979615,"share":"https://ttm.financial/m/news/1128199198?lang=&edition=fundamental","pubTime":"2022-02-16 10:46","market":"us","language":"en","title":"Two Reasons to Skip Ocugen Stock Despite Some Good News","url":"https://stock-news.laohu8.com/highlight/detail?id=1128199198","media":"InvestorPlace","summary":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a ","content":"<html><head></head><body><p><b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) has been one of the most explosive stocks on the market in the last year.</p><p>From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.</p><p>It’s all thanks to its coronavirus vaccine, Covaxin.</p><p>Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.</p><p>Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.</p><p>That’s all great news.</p><p>No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.</p><p>However, I wouldn’t rush to buy the stock. There are some major issues.</p><p><b>Issue No. 1: Ocugen’s Commercialization Agreement with Bharat Biotech</b></p><p>At the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.</p><p>That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.</p><p><b>Issue No. 2: OCGN Stock is Losing Money</b></p><p>Worse, the company isn’t bringing in any money, and losses continue to pile up.</p><p>In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to <i>Motley Fool</i> contributor David Jagielski:</p><blockquote>“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”</blockquote><p><b>Fortunately, the Vaccine Isn’t Ocugen’s Only Catalyst</b></p><p>That being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.</p><p>In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.</p><p>Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”</p><p><b>The Bottom Line on OCGN Stock</b></p><p>The story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.</p><p>Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.</p><p>Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.</p><p>I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Reasons to Skip Ocugen Stock Despite Some Good News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Reasons to Skip Ocugen Stock Despite Some Good News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...</p>\n\n<a href=\"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128199198","content_text":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.It’s all thanks to its coronavirus vaccine, Covaxin.Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.That’s all great news.No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.However, I wouldn’t rush to buy the stock. There are some major issues.Issue No. 1: Ocugen’s Commercialization Agreement with Bharat BiotechAt the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.Issue No. 2: OCGN Stock is Losing MoneyWorse, the company isn’t bringing in any money, and losses continue to pile up.In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to Motley Fool contributor David Jagielski:“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”Fortunately, the Vaccine Isn’t Ocugen’s Only CatalystThat being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”The Bottom Line on OCGN StockThe story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095472787,"gmtCreate":1644980502284,"gmtModify":1676533983142,"author":{"id":"3571707309049146","authorId":"3571707309049146","name":"benjaminlsk","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":1,"crmLevelSwitch":0,"idStr":"3571707309049146","authorIdStr":"3571707309049146"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095472787","repostId":1128199198,"repostType":4,"repost":{"id":"1128199198","kind":"news","pubTimestamp":1644979615,"share":"https://ttm.financial/m/news/1128199198?lang=&edition=fundamental","pubTime":"2022-02-16 10:46","market":"us","language":"en","title":"Two Reasons to Skip Ocugen Stock Despite Some Good News","url":"https://stock-news.laohu8.com/highlight/detail?id=1128199198","media":"InvestorPlace","summary":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a ","content":"<html><head></head><body><p><b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) has been one of the most explosive stocks on the market in the last year.</p><p>From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.</p><p>It’s all thanks to its coronavirus vaccine, Covaxin.</p><p>Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.</p><p>Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.</p><p>That’s all great news.</p><p>No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.</p><p>However, I wouldn’t rush to buy the stock. There are some major issues.</p><p><b>Issue No. 1: Ocugen’s Commercialization Agreement with Bharat Biotech</b></p><p>At the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.</p><p>That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.</p><p><b>Issue No. 2: OCGN Stock is Losing Money</b></p><p>Worse, the company isn’t bringing in any money, and losses continue to pile up.</p><p>In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to <i>Motley Fool</i> contributor David Jagielski:</p><blockquote>“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”</blockquote><p><b>Fortunately, the Vaccine Isn’t Ocugen’s Only Catalyst</b></p><p>That being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.</p><p>In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.</p><p>Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”</p><p><b>The Bottom Line on OCGN Stock</b></p><p>The story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.</p><p>Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.</p><p>Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.</p><p>I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Reasons to Skip Ocugen Stock Despite Some Good News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Reasons to Skip Ocugen Stock Despite Some Good News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...</p>\n\n<a href=\"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128199198","content_text":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.It’s all thanks to its coronavirus vaccine, Covaxin.Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.That’s all great news.No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.However, I wouldn’t rush to buy the stock. There are some major issues.Issue No. 1: Ocugen’s Commercialization Agreement with Bharat BiotechAt the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.Issue No. 2: OCGN Stock is Losing MoneyWorse, the company isn’t bringing in any money, and losses continue to pile up.In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to Motley Fool contributor David Jagielski:“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”Fortunately, the Vaccine Isn’t Ocugen’s Only CatalystThat being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”The Bottom Line on OCGN StockThe story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095476709,"gmtCreate":1644980382518,"gmtModify":1676533983127,"author":{"id":"3557823792637532","authorId":"3557823792637532","name":"ZhiLing","avatar":"https://static.tigerbbs.com/40d052b9f7db59b50f72a3cbcbc99234","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3557823792637532","authorIdStr":"3557823792637532"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095476709","repostId":1128199198,"repostType":4,"repost":{"id":"1128199198","kind":"news","pubTimestamp":1644979615,"share":"https://ttm.financial/m/news/1128199198?lang=&edition=fundamental","pubTime":"2022-02-16 10:46","market":"us","language":"en","title":"Two Reasons to Skip Ocugen Stock Despite Some Good News","url":"https://stock-news.laohu8.com/highlight/detail?id=1128199198","media":"InvestorPlace","summary":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a ","content":"<html><head></head><body><p><b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) has been one of the most explosive stocks on the market in the last year.</p><p>From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.</p><p>It’s all thanks to its coronavirus vaccine, Covaxin.</p><p>Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.</p><p>Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.</p><p>That’s all great news.</p><p>No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.</p><p>However, I wouldn’t rush to buy the stock. There are some major issues.</p><p><b>Issue No. 1: Ocugen’s Commercialization Agreement with Bharat Biotech</b></p><p>At the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.</p><p>That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.</p><p><b>Issue No. 2: OCGN Stock is Losing Money</b></p><p>Worse, the company isn’t bringing in any money, and losses continue to pile up.</p><p>In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to <i>Motley Fool</i> contributor David Jagielski:</p><blockquote>“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”</blockquote><p><b>Fortunately, the Vaccine Isn’t Ocugen’s Only Catalyst</b></p><p>That being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.</p><p>In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.</p><p>Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”</p><p><b>The Bottom Line on OCGN Stock</b></p><p>The story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.</p><p>Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.</p><p>Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.</p><p>I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Reasons to Skip Ocugen Stock Despite Some Good News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Reasons to Skip Ocugen Stock Despite Some Good News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months ...</p>\n\n<a href=\"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2022/02/two-reasons-to-skip-ocugen-stock-despite-some-good-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128199198","content_text":"Ocugen(NASDAQ:OCGN) has been one of the most explosive stocks on the market in the last year.From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%.It’s all thanks to its coronavirus vaccine, Covaxin.Co-developed with India’s Bharat Biotech, the vaccine had a 77.8% overall efficacy rate in a phase-3 study. In addition, the World Health Organization issued emergency use authorization for the vaccine to be used globally.Also, “previous studies showed that Covaxin was also effective at immunizing patients against the Alpha, Beta, Delta, Zeta, and Kappa variants of Covid-19,” as noted by TipRanks.That’s all great news.No wonder Noble Financial analyst Robert LeBoyer has an outperform rating on the stock, with a price target of $15 a share.However, I wouldn’t rush to buy the stock. There are some major issues.Issue No. 1: Ocugen’s Commercialization Agreement with Bharat BiotechAt the moment, Ocugen has a commercialization agreement with Bharat Biotech that only includes the United States and Canada.That means OCGN only makes money from the vaccine from sales in the U.S. and Canada. Worse, the company hasn’t received authorization from either country. Plus, even if it did receive authorization, the U.S. already has vaccines in use.Issue No. 2: OCGN Stock is Losing MoneyWorse, the company isn’t bringing in any money, and losses continue to pile up.In its third quarter, the company had no revenue. Plus, in the first nine months of 2021, it posted a net earnings loss of $43.78 million. That was worse than the $30.58 million posted year over year. Plus, according to Motley Fool contributor David Jagielski:“Over the same time frame, Ocugen has used up $35.1 million on just its day-to-day operating activities. That’s problematic given that the cash Ocugen reported at the end of the period was just $107.5 million.”Fortunately, the Vaccine Isn’t Ocugen’s Only CatalystThat being said, Ocugen is in pre-clinical trials for dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.In addition, the U.S. Food and Drug Administration recently accepted the company’s Investigational New Drug application (IND) to initiate clinical trials of its gene therapy treatment for retinitis pigmentosa.Also, according to a company press release, “The European Medicines Agency (EMA) granted Ocugen broad orphan medicinal product designation in 2021 for OCU400 for the treatment of both retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) — meaning that, if approved, OCU400 by itself could treat these diseases that are rooted in mutations of more than 175 different genes.”The Bottom Line on OCGN StockThe story behind OCGN certainly is solid; there’s some good news with its phase-3 vaccine trials.Plus, analyst price targets on the stock have an average of $8.88, with one analyst giving it a target price of $15.Unfortunately, it’s burning through cash. It’s not generating revenues. In addition, unless it can get emergency use authorization in the U.S. and Canada, it’s not likely to make money. Coupled with fierce coronavirus vaccine competition, the existing agreement with Bharat Biotech isn’t actually good for the company.I just don’t see how the OCGN stock could come anywhere near $15 a share on that. For now, avoid the stock. Unless some miracle happens, OCGN stock should be avoided.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":41,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}